What the label lists and what reports show
Florbetapir f 18 side effects
Florbetapir f 18's FDA label: “Most common adverse reactions (incidence ≥ 0.4%) were headache, musculoskeletal pain, increased blood pressure, nausea, fatigue, injection site reaction, anxiety, back pain, claustrophobia, dizziness, feeling cold, insomnia, and neck pain.” FAERS holds 113 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is amyloid related imaging abnormality-oedema/effusion (28 reports).
- No generic listed
Check it at the source: the florbetapir f 18 FDA label on DailyMed (effective December 11, 2025, Eli Lilly and Company); the FDA FAERS public dashboard.
What does the label list?
From the label: adverse reactionsMost common adverse reactions (incidence ≥ 0.4%) were headache, musculoskeletal pain, increased blood pressure, nausea, fatigue, injection site reaction, anxiety, back pain, claustrophobia, dizziness, feeling cold, insomnia, and neck pain.
Table 2: Adverse Reactions Reported in ≥ 0.4% of Adult Subjects Who Received AMYVID in Clinical Trials
| Adverse Reaction | a Includes the terms blood pressure increased and hypertension. b Includes the terms injection site hemorrhage, injection site irritation, and injection… c Includes the terms feeling cold and chills. AMYVID N=555 % |
|---|---|
| Headache | 1.8 |
| Musculoskeletal pain | 0.7 |
| Blood pressure increased a | 0.7 |
| Nausea | 0.7 |
| Fatigue | 0.5 |
| Injection site reaction b | 0.5 |
| Anxiety | 0.4 |
| Back pain | 0.4 |
| Claustrophobia | 0.4 |
| Dizziness | 0.4 |
| Feeling cold c | 0.4 |
| Insomnia | 0.4 |
| Neck pain | 0.4 |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedMost common adverse reactions (incidence ≥ 0.4%) were headache, musculoskeletal pain, increased blood pressure, nausea, fatigue, injection site reaction, anxiety, back pain, claustrophobia, dizziness, feeling cold, insomnia, and neck pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-545-5979 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of AMYVID was evaluated in 555 adult subjects who received AMYVID by intravenous injection in clinical trials. Table 2 shows adverse reactions reported in ≥ 0.4% of subjects from the clinical trials. Table 2: Adverse Reactions Reported in ≥ 0.4% of Adult Subjects Who Received AMYVID in Clinical Trials a Includes the terms blood pressure increased and hypertension. b Includes the terms injection site hemorrhage, injection site irritation, and injection site pain. c Includes the terms feeling cold and chills. …
Source: FDA drug label, NDA202008 (Avid Radiopharms Inc), as published by Eli Lilly and Company, effective December 11, 2025 (SPL set bb5a5043-0f51-11df-8a39-0800200c9a66), via openFDA; the full label on DailyMed
What do FAERS reports show?
113 reports list florbetapir f 18 among the medicines taken, each a report of something that happened, not proof the medicine caused it; 1 are coded as a death and 12 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 23 reactions below, 7 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Florbetapir f 18: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions